{
    "2021-08-11": [
        [
            {
                "time": "",
                "original_text": "康泰生物13价肺炎疫苗入局，“黄金单品”还剩多少空间？",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "13价肺炎疫苗",
                        "黄金单品"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "康泰生物：13价肺炎球菌结合疫苗在申请药品注册批件中，产品获得批签发合格证后才可上市销售",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "13价肺炎球菌结合疫苗",
                        "药品注册",
                        "批签发"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "“德尔塔”来势汹汹，疫苗研发竞速之下，这场病毒战争到底如何继续？",
                "features": {
                    "keywords": [
                        "德尔塔",
                        "疫苗研发",
                        "病毒战争"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "2020创新指数500强：康泰生物排名102位",
                "features": {
                    "keywords": [
                        "2020创新指数",
                        "康泰生物",
                        "排名102位"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "市场格局加速重塑，谁将成为中国的“疫苗之王”？",
                "features": {
                    "keywords": [
                        "市场格局",
                        "疫苗之王"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}